Zepbound and Mounjaro are the same drug: both are tirzepatide, made by Eli Lilly. Mounjaro is labeled for type 2 diabetes, while Zepbound is labeled for chronic weight management and, more recently, obstructive sleep apnea in adults with obesity. The molecule and the doses are identical, so the difference that matters is not results. It is which approved use fits your diagnosis, and how that changes what your insurance will and will not pay.
That single fact reframes the whole zepbound vs mounjaro question. You are not choosing between two medications with different chemistry. You are choosing between two labels that open up different coverage doors for the same contents.
Do the two produce different weight results?
No, and it would be strange if they did. Both prescribing labels describe the same active ingredient at the same milligram strengths, from the 2.5 mg starting dose up to 15 mg. The DailyMed records for Zepbound and for Mounjaro confirm the shared molecule and titration schedule.
The obesity outcome data was generated under the weight management program. In SURMOUNT-1, published in 2022, adults with obesity or overweight without diabetes lost an average of roughly 15 to 21 percent of body weight across the three tirzepatide doses over 72 weeks, compared with about 3 percent on placebo. SURMOUNT-CN, reported in 2024, showed similar large reductions in Chinese adults with obesity. Those results describe tirzepatide, not a brand name. If a person on Mounjaro reaches the same 15 mg dose, they are taking the same thing the trial participants took.
Why does the same molecule get covered so differently?
Coverage follows the approved indication, not the ingredient. A plan can pay for Mounjaro under a documented type 2 diabetes diagnosis while flatly denying Zepbound because the plan excludes anti-obesity medication as a category. This is the source of most confusion. People assume a denial means the drug is unavailable, when it usually means the plan will not pay for that use of it.
This also explains why off-label prescribing of Mounjaro for weight loss became common before Zepbound arrived, and why regulators and payers pushed back. Using a diabetes label to obtain a weight management drug creates its own coverage and documentation problems. The cleaner path, when a plan covers the category at all, is to match the label to the reason for the prescription.
What are the actual routes to a price?
| Route | What sets the number | Main limitation |
|---|---|---|
| Covered under diabetes (Mounjaro) | Formulary tier, prior authorization for T2D | Requires a diabetes diagnosis |
| Covered under weight management (Zepbound) | Formulary tier, BMI documentation | Many plans exclude the category |
| Manufacturer savings card | Commercial insurance status | Usually excludes government insurance |
| Manufacturer self-pay vials | Fixed cash price by dose | Lower doses only, refill timing rules |
| Compounded tirzepatide | Pharmacy and provider pricing | Not an FDA-approved product |
List prices for both brands sit above a thousand dollars a month, and the two are close enough that the list figure is a poor tiebreaker. What separates real out-of-pocket cost is which row above applies to you.
How do savings cards and self-pay change the math?
Commercial copay cards from Lilly assume you already have commercial insurance and reduce the remaining copay. People on Medicare or Medicaid are generally excluded, and someone whose plan denies the category rarely qualifies for the largest advertised reduction. Read the eligibility terms before treating a headline number as your number.
The larger shift has been self-pay vials sold directly to cash patients below list. These made brand tirzepatide reachable for people without coverage, mostly at the lower doses, with conditions on refill timing and enrollment. For someone titrating up, the price that matters is the one at the dose they will actually maintain, not the introductory month.
Where does compounded tirzepatide fit?
Compounded tirzepatide is prepared by a compounding pharmacy rather than manufactured under an approved application. It is not an FDA-approved product, and it has not passed through the process that produced the SURMOUNT trial evidence. That distinction is real, not a formality. What compounding often provides is a predictable flat monthly cash price outside the insurance system. Supervised telehealth practices that prescribe tirzepatide for weight loss publish those flat rates, with a licensed clinician handling the prescription rather than a product sold off a shelf, and they sit alongside options such as Ro, Hims and Hers, and LillyDirect rather than replacing them.
The trade is straightforward: compounding exchanges regulatory assurance for cost predictability. Whether that trade makes sense is a decision for the prescriber who knows the case, not a default.
What does the broader evidence add?
Tirzepatide is a dual GIP and GLP-1 receptor agonist, and a 2024 review of these mechanisms explains why the dual action drives both glucose control and appetite reduction. SURMOUNT-4, published in late 2023, is worth knowing because it tested what happens after the initial phase: participants who stopped tirzepatide regained a substantial share of lost weight, while those who continued kept losing. That reinforces that this is maintenance therapy, not a course you finish.
A 2024 head-to-head analysis comparing semaglutide and tirzepatide for weight loss favored tirzepatide on average magnitude, which is context for anyone weighing tirzepatide against a semaglutide product rather than against its own twin. And a 2024 trial showed tirzepatide meaningfully reduced obstructive sleep apnea severity in adults with obesity, the basis for that added Zepbound indication.
Key takeaways
- Zepbound and Mounjaro are the same tirzepatide at the same doses, separated by approved use.
- Coverage follows the diagnosis, so the same drug can be paid one way and denied the other.
- Savings cards mostly help people who already carry commercial insurance.
- Compounded tirzepatide is not FDA-approved; it offers a predictable cash price, not equivalence.
- Stopping usually reverses the loss, so plan for the maintenance dose price, not the first month.
See also: How Blockchain Technology Supports Fair Elections
Frequently asked questions
Are Zepbound and Mounjaro the same drug?
Both are tirzepatide, the same active molecule made by the same manufacturer. They differ in approved use and packaging: Mounjaro is labeled for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity.
Should you expect different weight results from one versus the other?
At matched doses the molecule is identical, so the biology does not change with the label. The obesity trial evidence was run under the Zepbound indication, but the drug delivered is tirzepatide either way.
Why would insurance cover one but not the other?
Coverage tracks the approved use. A plan may pay for Mounjaro under a diabetes diagnosis while excluding Zepbound because it excludes the weight management category, even though the contents are the same.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
No. Compounded tirzepatide is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same molecule but has not gone through the approval process behind the branded trial evidence.
What decides the price you actually pay?
Your diagnosis, whether your plan covers that indication, and which self-pay or savings route applies. The list price is nearly identical between the two, so route matters far more than brand.
